In addition, CXCL5‐neutralizing antibodies effectively attenuated the inflammatory response, diffused alveolar injury and pulmonary edema, and reduced the expression levels of MMP‐2 and MMP‐9 in ARDS mouse models.292. Here, CXCL5 is linked to acute respiratory distress syndrome.